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ABSTRACT
Abnormal cholesterol level is a major risk factor in the development of atherosclerosis, which is a
fundamental derangement in cardiovascular diseases. Any efforts should be undertaken to lower
blood cholesterol levels. Among dietary interventions, capsaicinoid supplementation is also consid-
ered as a novel cholesterol-lowering approach, but human studies concluded contradictory results
about its effectiveness. The present meta-analysis aimed at determining the effects of capsaici-
noids on serum lipid profile in humans. We searched the PubMed, EMBASE, and CENTRAL data-
bases from inception to February 2021. We included 10 controlled studies, which involved 398
participants. We found that dietary capsaicinoid supplementation alone or in combination with
other substances significantly (p¼ 0.004 and 0.001, respectively) reduced serum total cholesterol
level compared to controls with an overall standardized mean difference of 0.52 (95% confi-
dence interval: 0.83, 0.21). Capsaicinoids also decreased low-density lipoprotein level signifi-
cantly (p¼ 0.035), whereas no effect was observed on serum levels of high-density lipoprotein and
triglycerides. Our findings provide novel quantitative evidence for the efficacy of dietary capsaicin
supplementation in lowering serum total cholesterol and low-density lipoprotein levels in humans.
To validate our conclusion, further randomized controlled trials in a diverse population of adult
humans receiving dietary capsaicinoid supplementation are warranted.
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Introduction
Atherosclerosis represents a significant challenge for patients
and healthcare worldwide, including developed and develop-
ing countries alike (Herrington et al. 2016), and it is a main
underlying cause of ischemic heart disease and stroke,
which, respectively, accounted for about 9 and 6 million
deaths globally in 2015 (Roth et al. 2017). The development
of atherosclerosis entails the formation of fatty deposits (pla-
ques) in the vascular wall, which thickens the wall, but, in
turn, narrows the lumen of the vessels, therefore reducing
the blood flow and tissue blood supply (Lusis 2000).
Cholesterol is a key substance, which contributes to the
buildup of plaques, hence high cholesterol level is a
well-acknowledged risk factor for cardiovascular diseases,
including atherosclerosis (Ference et al. 2017). Different
pharmacological therapies, for example, statins, selective
cholesterol absorption inhibitors, and resins, are used to
decrease abnormally high serum cholesterol (Ray et al.
2019), but lifestyle changes are also fundamental in
controlling cholesterol levels. Important advantages of
changes in lifestyle (e.g., diet and physical activity) are the
better compliance of the patients and the absence of possibly
severe, adverse effects (e.g., liver failure, myopathy, and dia-
betes mellitus), both of which can hinder pharmacological
therapies (Thompson, Clarkson, and Karas 2003; Sattar et al.
2010). Currently, there are different dietary recommenda-
tions that aim at reducing serum cholesterol levels (Arnett
et al. 2019), but the hunt for novel and effective, choles-
terol-lowering natural ingredients is still ongoing.
A candidate among such natural ingredients is capsaicin,
which is the first known agonist of the transient receptor
potential vanilloid-1 (TRPV1) channel, formerly also known
as the capsaicin receptor [for a review, see Romanovsky
et al. (2009)]. TRPV1 contributes to the maintenance of
energy metabolism in humans through different mecha-
nisms, including the regulation of energy expenditure (Ludy,
Moore, and Mattes 2012), body temperature (Garami et al.
2020), and body mass (Zsiboras et al. 2018). Data from ani-
mal experiments also suggest that TRPV1 activation
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increases fat oxidation in rodents (Leung 2014), and that
capsaicin administration decreases serum levels of choles-
terol and triglycerides in small mammals, such as mice, rats,
hamsters, and rabbits, although it should be also noted that
the beneficial effect was not shown in some studies [for a
recent systematic review, see Sanati, Razavi, and
Hosseinzadeh (2018)]. At present, the results about the effect
of TRPV1 agonists on serum cholesterol in human studies
are inconclusive. In different trials, TRPV1 agonists caused a
decrease (Yuan et al. 2016; Taghizadeh et al. 2017), no effect
(Kim et al. 2010; Hochkogler et al. 2017) or an increase
(Urbina et al. 2017) in serum cholesterol levels. In the pre-
sent meta-analysis, we wanted to amalgamate the available
data from human studies in order to determine the effects
of the TRPV1 agonist capsaicinoids on serum choles-
terol levels.
Methods
This meta-analysis was conducted in accordance with the
PRISMA (Preferred Reporting Items for Systematic reviews
and Meta-Analyses) guidelines (Moher et al. 2009)
(Supplementary material Table S1). The question was raised
in the PICO (Population, Intervention, Control, Outcome)
format: in adult human subjects we wanted to compare the
effect of TRPV1 agonists with placebo on serum total chol-
esterol level (as the primary outcome). Secondary outcome
measures included triglyceride, lipoprotein component, fast-
ing glucose and insulin levels. This meta-analysis has been
registered with PROSPERO International Prospective
Register of Systematic Reviews (registration number:
CRD42020162735).
Search strategy
We searched the PubMed, EMBASE, and CENTRAL
(Cochrane Central Register of Controlled Trials) databases
from inception until February 20, 2021 to identify eligible
papers for the meta-analysis. The used search term was
“(capsa OR capsi OR TRPV1 OR vanilloid) AND (LDL
OR HDL OR lipoprotein OR triglyceride OR cholester OR
"lipid").” The search was limited to human trials without
language and publication date restrictions. Two authors (LK,
AG) conducted the search separately; disagreements were
resolved by consensus, if needed, with the help of a third
party (ZR).
Selection of studies and data extraction
Two authors (LK, ZR) assessed study eligibility and
extracted data from the selected studies independently.
Studies were required to include the following: controlled
human trial design; a group with TRPV1 agonist administra-
tion; a placebo group; serum cholesterol level among the
outcome measures. The following data were extracted from
the eligible studies: author names, publication year, age,
body mass index (BMI), and number of the participants, as
well as, different outcome measures, viz., serum levels of
total cholesterol, high- and low-density lipoproteins (HDL
and LDL, respectively), triglycerides, as well as, fasting glu-
cose and insulin.
Evaluation of risk of bias and quality of evidence
The risk of bias was evaluated for all analyzed outcome
measures, i.e., serum levels of total cholesterol, HDL, LDL,
and triglycerides, as well as, for fasting plasma glucose and
insulin levels, within the studies. According to the revised
tool for assessing risk of bias in randomized trials (Rob 2)
(Sterne et al. 2019), we assessed the bias in the following
domains: randomization process, deviations from intended
intervention, missing outcome data, measurement of the
outcome, and selection of the reported result
(Supplementary material Tables S2–S5). If the trial was not
randomized, risk of bias was assessed with the ROBINS-I
(Risk Of Bias In Non-randomized Studies of Interventions)
tool (Supplementary material Table S6). The results of the
assessments were visualized with the “robvis” tool
(McGuinness and Higgins 2021).
The Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach was used
to evaluate the applicability of the evidence. According to
the GRADE system (Atkins et al. 2004), each outcome was
tested based on the following factors: study design, risk of
bias, indirectness, inconsistency, imprecision, and publica-
tion bias. The overall quality of the evidence for each out-
come could be “high,” “moderate,” “low,” or “very low.” The
basal grade was high for randomized controlled studies and
it was decreased by 1 grade for serious concerns or by 2 for
very serious concerns.
Statistical analysis
The statistical analysis was performed according to the
standard methods of meta-analysis by using the Stata/IC
16.0 software (StataCorp LLC, College Station, TX, USA).
Subjects were grouped as either administered with a TRPV1
agonist (i.e., intervention group) or not (i.e., controls). We
used standardized mean differences (SMDs) with 95% confi-
dence intervals (CIs) between intervention and control
groups as primary measure of the effect size on serum lipid,
glucose, and insulin level response at the end of the sub-
stance administration. For standardization, the differences in
means were divided by their corresponding pooled standard
deviation (SD) values, which was required because the dif-
ferent measuring methods, reported units, and TRPV1 agon-
ist dose ranges could result in different variances among the
study groups, and, therefore, influence the results. SMD val-
ues were compared by using the random effect model by
DerSimonian and Laird (1986), and then presented as
“forest plots”.
Statistical heterogeneity was determined by the I2 statis-
tical test (p< 0.1 indicating significant heterogeneity), as
previously (Olah et al. 2018). As an attempt to reduce het-
erogeneity, subgroups administered with capsaicin (and its
derivates) only and with capsaicinoids in mixture of other
supposedly active ingredients were analyzed separately. As
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in our recent study (Csenkey et al. 2019), publication bias
was assessed by the visual inspection of funnel plots
(Supplementary material Figures S3–S8). Quantitative evalu-
ation by Egger’s test (Egger et al. 1997) could be performed
only for total serum cholesterol and LDL levels, because in
case of the other outcome parameters the number of eligible
studies was lower than ten, which is the minimal number of
studies recommended for the test by the Cochrane
Handbook (Higgins et al. 2021).
Results
Search results
The search identified altogether 4,879 studies from the
PubMed, EMBASE, and CENTRAL databases (Figure 1). We
used built-in filters available on the website of the databases to
limit our search to humans and clinical trials, which resulted
in exclusion of 4,443 records. After removing 35 duplicates,
401 papers remained, which were manually screened on title
Figure 1. Flow chart of study selection and inclusion.
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and abstract for inclusion criteria. Full texts of 39 articles were
obtained and reviewed, which resulted in the selection of 11
studies that were found eligible for qualitative synthesis
(Ahuja and Ball 2006; Inoue et al. 2007; Kim et al. 2010; Kang
et al. 2016; Yuan et al. 2016; Hochkogler et al. 2017; Lee et al.
2017; Qin et al. 2017; Taghizadeh et al. 2017; Urbina et al.
2017; Arent et al. 2018). Manual search of the reference lists of
the eligible articles lead to the identification of three additional
studies (Snitker et al. 2009; Cha et al. 2013; Lim et al. 2015),
thereby increasing the total number of eligible studies to 14.
However, four of these studies could not be included in the
quantitative analysis, because they did not report appropriate
data for meta-analysis (Inoue et al. 2007; Snitker et al. 2009),
or the authors (Lee et al. 2017) analyzed the same participants’
data as an earlier study by Cha et al. (2013), which was already
included in our meta-analysis, or because the subjects did not
receive capsaicin, but instead they were administered with a
low dose (0.15mg/day) of nonivamide (Hochkogler et al.
2017), which has a potency of half of that of capsaicin
(Skofitsch, Donnerer, and Lembeck 1984). As a result, 10 stud-
ies were included in the meta-analyses (Ahuja and Ball 2006;
Kim et al. 2010; Cha et al. 2013; Lim et al. 2015; Kang et al.
2016; Yuan et al. 2016; Qin et al. 2017; Taghizadeh et al. 2017;
Urbina et al. 2017; Arent et al. 2018). We confirmed that our
search algorithm was sensitive enough by also adding “paprika
species” and “herbal mixtures” to the search key, which
extended search did not identify any additional studies eligible
for quantitative synthesis.
Study characteristics and quality
The descriptive characteristics of the analyzed studies are
presented in Table 1. All 10 studies were controlled trials: 8
with parallel placebo control (Kim et al. 2010; Yuan et al.
2016; Qin et al. 2017; Taghizadeh et al. 2017; Urbina et al.
2017; Arent et al. 2018), and 2 with crossover designs
(Ahuja and Ball 2006; Kang et al. 2016). Except for one trial
(Kang et al. 2016), all studies were randomized. The dur-
ation of the trials varied from 4 to 12weeks, but all of them
could be considered as short term, lasting for less than three
months. Apart from a BMI of 26-32, the subjects had no
diagnosed health issues, except for one study (Yuan et al.
2016), which recruited women with postprandial diabetes
mellitus. With regards to substance administration, capsaicin
was used in all studies, but in two trials (Taghizadeh et al.
2017; Arent et al. 2018), it was combined with other bio-
logically active compounds (Table 1). The daily dose range
of capsaicin (4-5mg) was similar in four of the analyzed
studies (Kang et al. 2016; Yuan et al. 2016; Qin et al. 2017;
Urbina et al. 2017), while 100mg was used in the study by
Taghizadeh et al. (2017) and 22mg by Ahuja and Ball
(2006). The applied dosage was not reported in four papers
(Kim et al. 2010; Cha et al. 2013; Lim et al. 2015; Arent
et al. 2018).
According to the risk of bias analysis (Supplementary
material Tables S2–S6), six studies were considered overall
as high risk (Ahuja and Ball 2006; Kim et al. 2010; Cha
et al. 2013; Lim et al. 2015; Urbina et al. 2017; Arent et al.
2018), two studies as moderate risk (Kang et al. 2016; Qin
et al. 2017), and two studies as low risk (Yuan et al. 2016;
Taghizadeh et al. 2017).
By using the GRADE approach, the overall quality of evi-
dence was evaluated as low in case of lipid parameters, while
as very low in case of glucose and insulin. The summary of
findings and the detailed evaluation using the GRADE sys-
tem are shown in Supplementary material Tables S7 and S8.
It should be noted, however, that despite the suitability of
GRADE for developing clinical guidelines, its applicability is
questionable in food-based dietary guidelines, in which field
there are still inconsistencies for rating evidence quality
(Blake et al. 2018). Therefore, our GRADE results should be
taken with care.
Effects on lipid parameters and other outcomes
First, we analyzed the effect of dietary capsaicin supplemen-
tation on the serum total cholesterol level by comparing the
cholesterol levels between the intervention and control
groups at the end of the trials. Studies which used capsaici-
noids only (Ahuja and Ball 2006; Kim et al. 2010; Cha et al.















Ahuja and Ball (2006) RCRT Australia 27/27 46.0 (12.0) 26.6 (4.9) Chili supplement approx. 22b 4
Arent et al. (2018) RCT USA 18/18 36.9 (10.2) NR METABO pillc NR 8
Cha et al. (2013) RCT China 30/30 42.6 (1.9) 27.1 (0.7) Kochujang pill NR 12
Kang et al. (2016) NRCRT China 12/12 27.8 (3.8) 22.4 (3.2) Chili supplementd 5 6
Kim et al. (2010) RCT China 14/14 NR 26.4 (2.5) Chili supplement NR 12
Lim et al. (2015) RCT China 13/13 42.0 (7.7) 26.9 (4.5) Kochujang pill NR 12
Qin et al. (2017) RCT China 17/18 43.5 (5.4) 26.3 (2.9) Pod pepper powder 4 12
Taghizadeh et al. (2017) RCT Iran 25/25 33.7 (7.2) 32.4 (4.6) Dietary supplemente 100 8
Urbina et al. (2017) RCT USA 28/22 29.0 (2.0) 27.5 (6.0) Chili supplement 4 12
Yuan et al. (2016) RCT China 22/20 30.4 (4.5) 27.0 (3.6) Chili powder 4 4
BMI, body mass index; NR, not reported; NRCRT, non-randomized cross-over trial; RCRT, randomized cross-over trial; RCT, randomized controlled trial.
aData are reported as mean (standard deviation).
bBased on the reported capsaicin concentrations in cayenne pepper (Al Othman et al. 2011).
cContaining capsaicin, caffeine, raspberry ketone, garlic organosulfur, vitamin B, chromium, and gingerols.
dContaining 1.05mg/g capsaicin, 0.58mg/g dihydrocapsaicin, and 0.12mg/g nordihydrocapsaicin.
eConsisting of 125mg green tea, 25mg capsaicin, and 50mg ginger.
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2013; Lim et al. 2015; Kang et al. 2016; Yuan et al. 2016;
Qin et al. 2017; Urbina et al. 2017) and capsaicinoids com-
bined with other active ingredients (Taghizadeh et al. 2017;
Arent et al. 2018) were included as separate subgroups in
the forest plot (Figure 2). Dietary capsaicinoid supplementa-
tion markedly (p¼ 0.004) reduced serum total cholesterol
compared to the controls (SMD ¼ 0.57; CI, 0.95,
0.18). With regards to capsaicinoid-containing mixtures,
both of the included studies seemed to decrease serum total
cholesterol, however, there was no significant effect in the
individual studies or on average (SMD ¼ 0.32; CI, 0.75,
0.11; p¼ 0.141). The overall effect of all capsaicionoid sup-
plementations (i.e., alone and in combination; n¼ 195) was
a significant (p¼ 0.001) decrease in serum total cholesterol,
as compared to the control groups (n¼ 203) with an SMD
of 0.52 (CI, 0.83, 0.21).
Next, we wanted to know which component of total chol-
esterol is affected the most by capsaicionoids. We found suf-
ficient data to analyze the changes in LDL, triglyceride, and
HDL levels in response to dietary capsaicinoid
supplementation. Similarly as in Figure 2, in the remaining
forest plots we also analyzed the capsaicinoid alone and
mixture subgroups separately, if applicable. At the end of
the trials, the LDL level was lower (as indicated by a nega-
tive SMD) in the capsaicinoid-treated groups than in con-
trols in the most of the studies (Ahuja and Ball 2006; Cha
et al. 2013; Lim et al. 2015; Kang et al. 2016; Yuan et al.
2016; Urbina et al. 2017), whereas it was higher in two stud-
ies (Kim et al. 2010; Qin et al. 2017) (Figure 3). The aver-
aged SMD was not significantly different in either the
capsaicinoid alone or mixture subgroups. However, the
overall average SMD, calculated from all 10 studies, was
0.30 (CI 0.57, 0.02), indicating a significant (p¼ 0.035)
decrease in the capsaicinoid-treated group.
Capsaicinoids did not have a significant effect on serum
triglyceride levels, when administered alone (SMD ¼ 0.46;
CI, 1.49, 0.57) or in a mixture (SMD ¼ 0.19; CI, 0.62,
0.23) (Figure 4). The overall effect (including both sub-
groups) was also not statistically significant (SMD ¼ 0.39;
CI, 1.15, 0.37). When we compared serum HDL levels
Figure 2. Forest plot of the effects of capsaicinoids (top) and capsaicinoid-containing mixtures (bottom) on serum total cholesterol level. Here, and in Figures 3–5,
for each study, we calculated the difference between serum cholesterol levels in the capsaicinoid-treated group and the control group at the end of the interven-
tion period. For all studies, the differences in means were standardized (based on variances) to obtain standardized mean differences (SMDs). The SMDs and 95%
confidence intervals (CI) are used as primary measures of effect size and are shown in the forest plot. Black circles represent the SMD for each study, while the left
and right horizontal arms of the circles indicate the corresponding CI. The size of the gray box is proportional to the sample size and inversed variance. The rhom-
bus represents the average SMD calculated from the SMDs of the individual studies in a subgroup (top and middle) and in all studies (bottom). The horizontal diag-
onal of the rhombus represents the CI, while the vertical diagonal of the rhombus points at the SMD value of the subgroup or of all studies. The dashed line is
determined by the vertical diagonal of the bottom rhombus and indicates the SMD of all studies in the forest plot. There was no significant difference between the
two subgroups (Q¼ 0.709; p¼ 0.400). SD, standard deviation.
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between the capsaicinoid-treated and control groups, we
found no significant change in SMD, regardless from
whether the capsaicinoids were administered alone (SMD ¼
0.05; CI, 0.37, 0.47) or in combination with other substan-
ces (SMD ¼ 0.31; CI, 0.82, 0.21) (Figure 5). The overall
effect was negligible (SMD ¼ 0.03; CI, 0.37, 0.32).
In addition to the lipid parameters, we also analyzed two
indicators of carbohydrate metabolism: fasting blood glucose
and insulin. We did not find a significant effect of dietary
capsaicinoid supplementation on either of these parameters
as compared to the placebo group (Supplementary material
Figures S1 and S2). The SMDs between capsaicinoid-treated
and control groups were 0.41 (CI, 0.26, 1.07) for glucose
and 0.28 (CI, 0.25, 0.82) for insulin.
Qualitative synthesis
Four studies were not included in the meta-analysis, but
were retained for qualitative review. All four studies had
randomized controlled design. In one of these articles, Lee
et al. (2017) analyzed the data from the same participants as
a previous study by Cha et al. (2013), which was included in
the meta-analysis. Accordingly, the study design and
characteristics of participants were the same in the two stud-
ies, and the effects of capsaicinoids on the outcome parame-
ters were also similar.
In two studies, the authors stated that TRPV1 agonist
supplementation did not have a significant effect on lipid
parameters (total cholesterol, LDL, HDL, and triglyceride),
but factual information about blood levels was not reported
(Inoue et al. 2007; Snitker et al. 2009). Despite the lack of a
significant effect on blood lipid parameters, both of these
studies reported a beneficial effect of TRPV1 agonists on
body fat mass. Inoue et al. (2007) assigned 44 subjects into
3 groups: ingestion of non-pungent capsinoids at 3 or
10mg/kg, or placebo, and showed that capsinoids enhance
energy expenditure and fat oxidation. In the study by
Snitker et al. (2009), 80 subjects were assigned into a capsi-
noid-treated (6mg) or placebo group, and the authors found
that capsinoids caused an augmented abdominal fat loss and
a near significant increase in fat oxidation.
Hochkogler et al. (2017) studied the effects of noniva-
mide at a low dose of 0.15mg/day (versus a control group)
in 18 participants. Although the potency of nonivamide is
only half of that of capsaicin (Skofitsch, Donnerer, and
Lembeck 1984), it prevented dietary-induced fat accumula-
tion even at the applied low dose. The authors hypothesized
Figure 3. Forest plot of the effects of capsaicinoids (top) and capsaicinoid-containing mixtures (bottom) on serum low-density lipoprotein (LDL) cholesterol level.
There was no significant difference between the two subgroups (Q¼ 0.006; p¼ 0.940). CI, confidence interval; SD, standard deviation; SMD, standardized
mean difference.
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that nonivamide affects lipid assimilation by reducing adipo-
genesis, however, significant change in blood lipid parame-
ters was not detected (Hochkogler et al. 2017).
Discussion
In the present study, we show that dietary intake of TRPV1
agonists reduced serum total cholesterol and LDL levels in
humans, to our knowledge for the first time, with meta-ana-
lysis of the available controlled trials, including a total of 10
studies with 398 subjects.
High serum cholesterol is a main risk factor for athero-
sclerotic cardiovascular disease (Stone and Grundy 2019),
which is the major component of cardiovascular diseases
responsible for over 4 million deaths in Europe annually
(Townsend et al. 2015). Lowering cholesterol levels reduces
the risk for atherosclerosis, which explains why current
guidelines recommend substantial reduction in serum chol-
esterol level, most of all in that of LDL (Mach et al. 2020).
While different cholesterol-lowering pharmacological treat-
ments are available, evidence on the influence of lifestyle
changes and functional foods on lipoproteins is growing.
Lifestyle changes, alone or in combination with drugs, are
still among the recommended intervention strategies of
reducing cardiovascular risk (Mach et al. 2020).
A beneficial effect of TRPV1 agonists, particularly capsa-
icin, on blood cholesterol has been long sought based on
data obtained in animal experiments showing that capsaicin
improved obesity-related metabolic disorders, also including
dyslipidemia (Panchal, Bliss, and Brown 2018; Li et al.
2020). Human studies, however, lead to contradictory find-
ings, thereby questioning whether the cholesterol-lowering
effects of TRPV1 agonists observed in experimental models
are applicable for humans. Indeed, the effect of dietary sup-
plementation with capsaicinoids on serum cholesterol in
humans ranged from beneficial to neutral to unfavorable.
However, the number of the controlled human studies on
the effect of capsaicinoids on cholesterol serum levels was
too small until recently for a quantitative synthesis of their
overall result, since six trials eligible for such synthesis were
published in the last five years (Kang et al. 2016; Yuan et al.
2016; Qin et al. 2017; Taghizadeh et al. 2017; Urbina et al.
2017; Arent et al. 2018). In the present meta-analysis, we
performed the long-sought quantitative synthesis of the
available data and showed that dietary capsaicinoid supple-
mentation lowers blood cholesterol levels in humans. When
we looked at the lipid components, we found that capsaici-
noids significantly decreased LDL levels, while the levels of
triglycerides and HDL were not affected by the treatment.
These findings indicate that the capsaicinoid-induced
Figure 4. Forest plot of the effects of capsaicinoids (top) and capsaicinoid-containing mixtures (bottom) on total serum triglyceride level. There was no significant
difference between the two subgroups (Q¼ 0.216; p¼ 0.642). CI, confidence interval; SD, standard deviation; SMD, standardized mean difference.
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reduction of total cholesterol is associated with a beneficial
alteration in lipid components, inasmuch as LDL, the harm-
ful component (Ference et al. 2017), decreases, while HDL,
the protective component (Rosenson et al. 2018), does not
change. Unfortunately, there was not enough data available
to study further lipid components (e.g., chylomicron, very-
low- and intermediate-DL).
The exact mechanism by which TRPV1 agonists affect
cholesterol levels could not be studied in the present work
(due to its meta-analysis nature) and remains subject for
further research. It is notable, however, that in healthy
human subjects, capsaicin ingestion increased thermogenesis
and activation of the sympathetic nervous system
(Matsumoto et al. 2000) and augmented fat oxidation during
exercise (Shin and Moritani 2007). Capsaicin and capsiate
were also shown to increase energy expenditure in humans
and proposed as novel therapeutic agents in obesity
(Zsiboras et al. 2018). A site for thermogenesis in humans is
the brown adipose tissue (Nedergaard and Cannon 2018),
which can be stimulated via the sympathetic nervous system
(e.g., in cold). It has been shown that adrenergic activation
of brown fat is protective against hypercholesterolemia in
mice (Berbee et al. 2015), and that its cold-induced activa-
tion by means of cold acclimation improved cholesterol
metabolism in human patients with hypercholesterolemia
(De Lorenzo et al. 1998). Adrenergic brown fat stimulation
can trigger intracellular mechanisms capable of increasing
the activation of lipases, which are responsible for the
mobilization of fatty acids that can be used for thermogen-
esis (Xu and Lopez 2018). These findings suggest a link
between capsaicin-induced thermogenesis, possibly via sym-
pathetic activation in brown fat, and the reduction in blood
cholesterol levels. It should be also noted that TRPV1
expression was described in brown and white adipocytes,
therefore capsaicin can even directly (i.e., independently of
adrenergic activation) regulate thermogenesis, adipocyte dif-
ferentiation, and expression of uncoupling proteins [for a
recent review, see Uchida et al. (2018)].
Alternative interactions between the TRPV1 channel and
cholesterol level may include the hunger hormone ghrelin.
Studies in mice and rats suggested that ghrelin inhibits
thermogenesis (Mano-Otagiri et al. 2009; Lin et al. 2014).
Interestingly, one of the studies, which was included in our
analysis, found that capsaicin administration markedly
(p< 0.01) decreased serum ghrelin concentration in the par-
ticipants (Kang et al. 2016). The presence of TRPV1 chan-
nels was shown in the human stomach (Faussone-Pellegrini
et al. 2005), which is the main site of ghrelin production
(Kojima and Kangawa 2005). Hence, a potential inhibitory
action of capsaicin on ghrelin production can not be
Figure 5. Forest plot of the effects of capsaicinoids (top) and capsaicinoid-containing mixtures (bottom) on serum high-density lipoprotein (HDL) cholesterol level.
There was no significant difference between the two subgroups (Q¼ 1.115; p¼ 0.291). CI, confidence interval; SD, standard deviation; SMD, standardized
mean difference.
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excluded. Moreover, a direct effect of cholesterol on TRPV1
was also suggested, as in cholesterol depletion the membrane
trafficking of TRPV1 channels is negatively affected, while
in cholesterol enrichment the activation of TRPV1 by capsa-
icin is inhibited (Morales-Lazaro and Rosenbaum 2019).
However, the physiological significance of this interaction
remains unknown.
The cholesterol-reducing effects of dietary TRPV1 agonists,
as also shown here, are of high importance, especially consider-
ing that these compounds were found to evoke further advanta-
geous effects on human bodily homeostasis. For instance,
decreased body mass (Leung 2014), increased energy expend-
iture (Zsiboras et al. 2018), reduced blood pressure (Sanati,
Razavi, and Hosseinzadeh 2018), as well as, lower blood sugar
and increased insulin sensitivity (Panchal, Bliss, and Brown
2018) were all reported in response to the administration of dif-
ferent TRPV1 agonists. Moreover, potent and selective pharma-
cological agents for the modulation of TRPV1 activity were also
developed and subjected to in-vivo testing. Depending on their
pharmacological profiles against the TRPV1 channel, these
compounds caused an increase, no change, or a decrease in the
body temperature of laboratory animals (Garami et al. 2018)
and humans (Garami et al. 2020). This raises the possibility that
through targeted modulation of the TRPV1 channel, and
thereby energy expenditure, some of the compounds might be
also used in the control of lipid metabolism.
Some limitations of our study must be also mentioned.
Although the number of studies was sufficient for meta-ana-
lysis, it was still relatively small. Only 10 controlled human
studies (9 randomized and 1 non-randomized) could be
included in the quantitative synthesis despite the extensive
literature search. Consequently, we could not perform some
of the planned analysis (e.g., subgroup analysis for sex and
food intake) in our study because of data unavailability. Due
to differences in study design and methodology, consider-
ably high between-study heterogeneity (indicated by an I2 of
46-96%) was observed in our analysis (Figures 3–5,
Supplementary material Figures S1 and S2). To account for
the presence of heterogeneity, we used the random-effects
model in all forest plots of our meta-analyses and performed
subgroup analysis. However, when we divided these studies
into subgroups in some cases heterogeneity was still present
and only two studies remained in a group, which does not
allow one to draw firm conclusions about the overall results
of such small subgroups. Based on visual inspection of the
funnel plots (Supplementary material Figures S3–S8), some
asymmetry may be present, indicating the possible existence
of publication bias, although when Egger’s test could be per-
formed, its results contradicted the presence of publication
bias (p¼ 0.973 for total cholesterol and p¼ 0.523 for LDL).
Nevertheless, two studies were identified by the literature
search, but could not be included in the quantitative synthe-
sis, because the authors opted not to report the results due
to the lack of statistically significant difference between the
treatment groups (Inoue et al. 2007; Snitker et al. 2009).
Finally, it should be also noted that the overall risk of bias
was judged as high in six of the ten analyzed studies
(Supplementary material Tables S2–S5), and the GRADE
certainty rating was low for the analyzed lipid parameters
(Supplementary material Tables S7 and S8). It is possible
that, despite all of our approaches to reduce methodological
errors, the low number, different design and quality, and
occasionally high heterogeneity of the analyzed studies may
have negatively impacted our results.
In conclusion, the present study provides novel quantita-
tive support to the beneficial effects of dietary capsaicin sup-
plementation on serum total cholesterol and LDL levels in
humans. Although the quantitative synthesis of the available
data is, to our knowledge, the most extensive in its field, we
also have to point out that the quality of evidence was eval-
uated as low in case of the analyzed lipid parameters and
that a few studies which might argue against our results
could not be included in the meta-analysis only in qualita-
tive synthesis. Consequently, further randomized controlled
trials are warranted to validate our findings and prove
unequivocally that dietary intake of TRPV1 agonists is an
effective intervention for lowering blood cholesterol levels.
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